Thymic stromal lymphopoietin gene promoter polymorphisms and expression levels in Graves’ disease and Graves’ ophthalmopathy

BMC Medical Genetics

Lei Wan⁴  Wen-Ling Liao⁴  Yu-Huei Liu⁵  Hung-Jung Lin³  Hui-Ju Lin¹  Fuu-Jen Tsai²  Kun-Hsi Tsai³ 

[1] Department of ophthalmology, China Medical University Hospital, Taichung, Taiwan;School of Post Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan;Department of Emergency Medicine, Chi Mei Hospital, Liouying, Tainan, Taiwan;Genetic Center, China Medical University Hospital, 404, Taichung, Taiwan;Graduate Institute of Integrated medicine, China Medical University, Taichung, Taiwan

关键词: Th17;    Thymic stromal lymphopoietin;    Graves’ ophthalmopathy;    Graves’ disease;   

Others  :  1177764
DOI  :  10.1186/1471-2350-13-116

 received in 2012-06-11, accepted in 2012-11-12,  发布年份 2012

【 摘 要 】

Background

Graves disease (GD) is an organ-specific autoimmune disease characterized by hyperthyroidism, diffuse goiter, autoantibodies against thyroid-specific antigens, and dermopathy. Studies of GD have demonstrated the importance of the Th2 and Th17 immune responses in mediating disease progression. In the present study, we investigated the role of a Th2 cytokine, thymic stromal lymphopoietin (TSLP), in GD and Th17 differentiation.

Methods

In this study, we genotyped 470 patients with GD at 3 single nucleotide polymorphisms (SNPs) in TSLP. In addition, the serum concentrations of TSLP were determined in 432 patients and 272 controls. Ten patients and controls each were further screened using in vitro Th17 differentiation assays. The SNPs were genotyped using ABI TaqMan® SNP genotyping assays. For the Th17 differentiation assays, peripheral blood mononuclear cells (PBMCs) isolated from the patients and controls were placed into Th17 differentiation media, and interleukin 17 expression levels were determined.

Results

Haplotype analysis indicated that patients with the Ht3 (TCC) haplotype have a 3.28-fold higher risk of developing GD (p = 0.007), whereas those with the Ht5 (TCG) haplotype had a 0.03-fold, reduced risk of developing GD (p = 1 × 10⁻¹⁴). SNP rs3806933 (p = 0.007) was associated with female Graves ophthalmopathy (GO). TSLP expression levels were higher in GD patients than in control subjects, and TLSP was also shown to promote the differentiation of Th17 cells in GD patients.

Conclusions

These results suggest that polymorphisms in TSLP may be used as genetic markers for the diagnosis and prognosis of GD. Furthermore, TLSP may be a target for treating GD.

【 授权许可】

   
2012 Tsai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Brown RS: Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr 2009, 21(4):523-528.
• [2]Comeau MR, Ziegler SF: The influence of TSLP on the allergic response. Mucosal Immunol 2010, 3(2):138-147.
• [3]He R, Geha RS: Thymic stromal lymphopoietin. Ann N Y Acad Sci 2010, 1183:13-24.
• [4]Ziegler SF, Artis D: Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010, 11(4):289-293.
• [5]Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A, Chiba T: Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy 2009, 39(1):89-100.
• [6]Figueroa-Vega N, Alfonso-Perez M, Benedicto I, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M: Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010, 95(2):953-962.
• [7]Nanba T, Watanabe M, Inoue N, Iwatani Y: Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid 2009, 19(5):495-501.
• [8]Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A: Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009, 66(3):390-402.
• [9]Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O’Farrelly C, Tubridy N, Mills KH: CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009, 183(11):7602-7610.
• [10]Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S: The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2011.
• [11]van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, Dolhain RJ, Lubberts E: Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011, 63(1):73-83.
• [12]Stappenbeck TS, Rioux JD, Mizoguchi A, Saitoh T, Huett A, Darfeuille-Michaud A, Wileman T, Mizushima N, Carding S, Akira S, et al.: Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy 2011, 7(4):355-374.
• [13]Hartgring SA, Willis CR, Dean CE Jr, Broere F, van Eden W, Bijlsma JW, Lafeber FP, van Roon JA: Critical proinflammatory role of thymic stromal lymphopoietin and its receptor in experimental autoimmune arthritis. Arthritis Rheum 2011, 63(7):1878-1887.
• [14]Harada M, Hirota T, Jodo AI, Hitomi Y, Sakashita M, Tsunoda T, Miyagawa T, Doi S, Kameda M, Fujita K, et al.: Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol 2011, 44(6):787-793.
• [15]Boniface K, Blom B, Liu YJ, de Waal Malefyt R: From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008, 226:132-146.
• [16]Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y: Interleukin (IL)-23 receptor is a major susceptibility gene for Graves’ ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008, 93(3):1077-1081.
• [17]Khalilzadeh O, Anvari M, Momen-Heravi F, Esteghamati A, Rashidi A, Mahmoudi M, Nikbin B, Amirzargar A: Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease. Clin Exp Med 2010, 10(2):123-128.
• [18]Inoue N, Watanabe M, Morita M, Tatusmi K, Hidaka Y, Akamizu T, Iwatani Y: Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol 2011, 163(3):318-323.
• [19]Inoue N, Watanabe M, Nanba T, Wada M, Akamizu T, Iwatani Y: Involvement of functional polymorphisms in the TNFA gene in the pathogenesis of autoimmune thyroid diseases and production of anti-thyrotropin receptor antibody. Clin Exp Immunol 2009, 156(2):199-204.
• [20]Liu YH, Chen RH, Wu HH, Liao WL, Chen WC, Tsai Y, Tsai CH, Wan L, Tsai FJ: Association of interleukin-1beta (IL1B) polymorphisms with Graves’ ophthalmopathy in Taiwan Chinese patients. Investig Ophthalmol Vis Sci 2010, 51(12):6238-6246.
• [21]Pedro AB, Romaldini JH, Takei K: Changes of serum cytokines in hyperthyroid Graves’ disease patients at diagnosis and during methimazole treatment. Neuroimmunomodulation 2011, 18(1):45-51.